Cancer Treatment Centers of America collaborated with Allscripts and NantHealth in order to implement a technical solution that will create better clinical workflows in the electronic health record of Allscripts Sunrise.
The integration makes it possible for Clinical Pathways to not interrupt the physician’ workflow while still informing the cancer treatment process. The interface was built with the assistance of hundreds of oncologists and is a vast collection of cancer care data. This advancement in technology make it possible to support clinical data, obtain real-time functionality, and make comparisons between the many different treatment options.
Clinical Pathways is helping to eliminates guesswork and is a system of treatment options, which is available for patients to review and choose from what is efficient and safe. Clinical Pathways has integrated therapies into the Alscripts Sunrise EHR , giving oncologists a curated list of care regimens. It also makes it possible to improve quality and efficiency and patient and their clinical teams can decide on the most suitable regimens. Clinical Pathways also helps to speed up the approval needed form insurance providers.
Eviti also plays a very important role in allowing physicians to gain the best regimens for their patients and opening communication with stakeholders for a much more efficient diagnosis.
Headquartered in Boca Raton, Florida, Cancer Treatment Centers of America is a network of five hospitals that provides care for adults who are fighting the battle against cancer. Cancer Treatment Centers of America provides radiation, surgery, cancer treatment, genomic testing, immunotherapy and chemotherapy in order to help their patients. Their methods are intended to provide their patients with emotional and physical help while managing the side effects of their treatments. Cancer Treatment Centers of America serves its patients from all around the world in its Tulsa, Atlanta, Chicago, Phoenix, and Philadelphia hospitals.
For more information follow CTCA on Twitter.